XPH:ARCA-SPDR S&P Pharmaceuticals (USD)

ETF | Health | NYSE Arca

Last Closing

USD 46.16

Change

0.00 (0.00)%

Market Cap

USD 0.50B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

Inception Date: 19/06/2006

Primary Benchmark: S&P Pharms Select Industry TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.35%

Management Expense Ratio: 0.35 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
CRTTF Cortus Metals Inc 4.39 %
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-02 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
XLV Health Care Select Sector SPDR.. 0.13 %

N/A

USD 40.26B
FHLC Fidelity® MSCI Health Care In.. 0.08 %

N/A

USD 2.86B
FXH First Trust Health Care AlphaD.. 0.63 %

N/A

USD 1.18B
XHE SPDR® S&P Health Care Equipme.. 0.35 %

N/A

USD 0.21B
IDNA iShares Genomics Immunology an.. 0.00 %

N/A

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF 0.50 %

N/A

USD 0.12B
XHS SPDR® S&P Health Care Service.. 0.35 %

N/A

USD 0.08B
HTEC Robo Global® Healthcare Techn.. 0.00 %

N/A

USD 0.05B
BBP Virtus LifeSci Biotech Product.. 0.79 %

N/A

USD 0.02B
BBC Virtus LifeSci Biotech Clinica.. 0.79 %

N/A

USD 0.01B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -44.55% 43% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.55% 43% F 12% F
Trailing 12 Months  
Capital Gain -38.17% 38% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.17% 38% F 12% F
Trailing 5 Years  
Capital Gain -41.50% 33% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.50% 33% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain -1.11% 14% F 28% F
Dividend Return -0.43% 14% F 21% F
Total Return 0.69% 68% D+ 17% F
Risk Return Profile  
Volatility (Standard Deviation) 15.79% 67% D+ 63% D
Risk Adjusted Return -2.70% 14% F 21% F
Market Capitalization 0.50B N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.